New drug xiflam aims to ease long COVID symptoms in small trial
NCT ID NCT06437223
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 2 study tested whether the oral drug Xiflam (tonabersat) can safely reduce symptoms of Long COVID compared to a placebo. Sixteen adults who had COVID-19 and then developed lasting symptoms for at least 12 weeks took part. Participants received either Xiflam or a placebo daily for 12 weeks, and researchers tracked changes in symptoms like fatigue, brain fog, and eye issues using patient-reported scales.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tonabersat (Xiflam)
What this could lead to
If successful, this could point toward a treatment to reduce the wide range of Long COVID symptoms, improving daily life for patients.
What could go wrong
This is a very small, early-phase trial with only 16 participants, so results may not apply to everyone. The drug may prove no better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts Eye Research and Surgery Institution (MERSI)
Waltham, Massachusetts, 02451, United States